You can find a more recent post on this topic here: Venlafaxine and Duloxetine: Pooled Analysis Shows No Increase in Risk of Malformations We receive a fair number of questions on the use of duloxetine [...]
While various studies have recently examined the prevalence of depression during pregnancy, few of these studies have examined how being an ethnic minority may influence the risk of antenatal depression. A new study from Oslo, Norway suggests that certain ethnic minorities may have a higher risk.
85 women with postpartum depression were randomized to receive acupuncture plus psychological intervention (five sessions per week) or treatment with fluoxetine (20 mg per day). The two groups were treated continuously for six weeks. Depressive symptoms were measured using the Hamilton Depression scale (HAMD).
While many women complain of psychological distress during infertility treatment, it has been somewhat unclear if the anxiety and depression women may experience is related to having to undergo infertility treatment or to the hormonal agents that are used as part of the treatment, or a combination of the two. While we know that changing levels of gonadal hormones, like estrogen, may affect mood and anxiety levels, we have very little information on the psychological effects of the hormone-modulating drugs used in assisted reproductive technology (ART).
During pregnancy, many women complain that they feel more forgetful or less sharp than before their pregnancy.
Women who take antidepressants for their depression must make a difficult decision when they plan to become pregnant. Should they continue their medication during pregnancy? Or should they stop? Although there is information to support the reproductive safety of at least some antidepressants, most women, understandably concerned about exposing their babies to medication, choose to discontinue their antidepressant during pregnancy.